Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Laquinimod Phase IIa Study in Active Crohn's Disease

This study has been completed.
Information provided by (Responsible Party):
Teva Pharmaceutical Industries Identifier:
First received: August 18, 2008
Last updated: January 24, 2012
Last verified: January 2012

The study aims to evaluate the safety and clinical effect of daily oral treatment of Laquinimod capsules in active moderate to severe Crohn's disease. This study will assess Laquinimod doses of 0.5mg /day to 2 mg/day in sequential dose groups (cohorts). Laquinimod is a novel immunomodulating drug which is currently in advanced stages of development by Teva Pharmaceuticals Ltd. for Multiple Sclerosis.

Condition Intervention Phase
Crohn's Disease
Drug: Laquinimod
Other: placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohorts, Dose Range Finding Study to Evaluate the Safety, Tolerability and Clinical Effect of Escalating Doses of Laquinimod in Active Moderate to Severe Crohn's Disease.

Resource links provided by NLM:

Further study details as provided by Teva Pharmaceutical Industries:

Primary Outcome Measures:
  • Safety, Tolerability, Clinical Effect - proportion of subjects in clinical remission, proportion of subjects who respond to treatment. [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]

Enrollment: 180
Study Start Date: May 2010
Study Completion Date: December 2011
Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Laquinimod
Laquinimod 0.5mg/day, 1mg/day, 1.5mg/day, 2mg/day (sequential cohorts)
Drug: Laquinimod
Laquinimod 0.5mg/day, 1mg/day, 1.5mg/day, 2mg/day, oral, for 8 weeks of treatment
Placebo Comparator: Placebo
Matching placebo
Other: placebo
Matching placebo for 8 weeks of treatment


Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Subjects diagnosed with Crohn's disease for at least 3 months prior to screening.
  2. Moderate to severe Crohn's disease patients as determined by the CDAI score

Exclusion Criteria:

  1. Subjects who have had recent bowel surgery
  2. Subjects with clinically significant GI obstructive symptoms
  3. Subjects with a clinically significant or unstable medical or surgical condition
  4. Subjects with unstable doses of standard of care medications (5-ASA, antibiotics, oral corticosteroids, immunosuppressants )
  5. Women who are pregnant or nursing or who intend to be during the study period.
  6. Women of child-bearing potential who do not practice an acceptable method of birth control
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00737932

  Show 34 Study Locations
Sponsors and Collaborators
Teva Pharmaceutical Industries
Principal Investigator: Geert D'Haens, MD PhD Imelda General Hospital
  More Information

No publications provided

Responsible Party: Teva Pharmaceutical Industries Identifier: NCT00737932     History of Changes
Other Study ID Numbers: CD-LAQ-201
Study First Received: August 18, 2008
Last Updated: January 24, 2012
Health Authority: European Union: European Medicines Agency

Additional relevant MeSH terms:
Crohn Disease
Digestive System Diseases
Gastrointestinal Diseases
Inflammatory Bowel Diseases
Intestinal Diseases processed this record on November 20, 2014